Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 13/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 13/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 13/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 13/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524654 | 0.94 | ATM (0.49) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3522629 | 0.93 | CACNA1F (0.55) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3523427 | 0.93 | CACNA1F (0.55) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3524822 | 0.91 | KIF11 (0.46) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL489754 | 0.89 | CACNA1F (0.54) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3521495 | 0.86 | CACNA1F (0.54) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3524664 | 0.86 | CACNA1F (0.54) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL15468439 | 0.86 | CACNA1F (0.49) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6699278 | 0.84 | PPARA (0.43) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S | |
| SCHEMBL3527456 | 0.84 | PPARA (0.43) | ALDH1A1KIF11CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | claimed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | claimed |
| EP-1542683-A2 | CALCIUM CHANNEL BLOCKERS | Diakron Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| EP-1515723-A2 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-03-23 | — | — | EP | claimed |
| WO-2004024153-A2 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | claimed |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | PULLELA PHANI KUMAR (US) | 2004-03-25 | — | — | US | claimed |
| WO-2003105854-A2 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2003-12-24 | — | — | WO | claimed |
| EP-1515723-B1 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2014-02-12 | — | — | EP | disclosed |
| EP-1515723-A2 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003105854-A2 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | ORAI1, RYR2, RYR1 | ALDH1A1 1580/4885KIF11 4058/4885CACNA1F 17/4885 |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | ORAI1, CACNA1B, CACNA1I | ALDH1A1 1674/4885KIF11 4373/4885CACNA1F 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.